They changed it to ventilator free survival at 28 days.
I interpret this as quite a bit of confidence that lenzilumab deters progression to ventilation. After all, the p value on that exact endpoint was 0.06 in the case control trial (though only out to 18 days, but I would argue you far more likely to lose more in the control group over days 19-28 than the lenzilumab group), and that was a *TINY* study!
If you extrapolate that out over 500+, the p value is likely to be way way lower than 0.05. In other words, that would mean the primary endpoint hits.
This is all good to me.
News 
Market Data 
Discover 
